Complaint over Lupin:
This is an action for patent infringement under the patent laws of the United States, Title 35 of the United States Code, arising from Lupin’s filing of an Abbreviated New Drug Application (“ANDA”) with the United States Food and Drug Administration(“FDA”), by which Lupin seeks approval to market a generic version of Pfizer Inc.’s pharmaceutical product, Toviaz ® , prior to the expiration of United States Patent Nos. 6,858,650(“the ‘650 patent”), 7,384,980 (“the ‘980 patent”), 7,855,230 (“the ‘230 patent”), 7,985,772 (“the‘772 patent”), and 8,338,478 (“the ‘478 patent”), which cover, interalia, Toviaz ® and/or its use.
On information, Lupin has submitted ANDA No. 204983 (“Lupin’s ANDA”) to the FDA, pursuant to 21 U.S.C. § 355(j), seeking approval to market fesoterodine fumarate extended-release tablets in 4 and 8 mg dosage strengths (“Lupin’sProduct”).
Case details:
Civil Action No. 1:13-cv-01153-UNA; no judge yet assigned.
Filed on June 28, 2013 in the U.S. District Court for the District of Delaware;
Complaint over Zydus:
On information belief, Zydus has submitted ANDA No. 204946 (“Zydus’s ANDA”) to the FDA, pursuant to 21 U.S.C. § 355(j), seeking approval to market fesoterodine fumarate extended-release tablets in 4 and 8 mg dosage strengths (“Zydus’sProduct”).
Case details:
Civil Action No. 1:13-cv-01154-UNA; no judge yet assigned.
Filed on June 28, 2013 in the U.S. District Court for the District of Delaware;
Complaint over Accordt:
Accord has submitted ANDA No. 205012(“Accord’s ANDA”) to the FDA, pursuant to 21 U.S.C. § 355(j), seeking approval to marketfesoterodine fumarate extended-release tablets in 4 and 8 mg dosage strengths (“Accord’sProduct”).
Case details:
Civil Action No. 1:13-cv-01155-UNA; no judge yet assigned.
Filed on June 28, 2013 in the U.S. District Court for the District of Delaware;
This is an action for patent infringement under the patent laws of the United States, Title 35 of the United States Code, arising from Lupin’s filing of an Abbreviated New Drug Application (“ANDA”) with the United States Food and Drug Administration(“FDA”), by which Lupin seeks approval to market a generic version of Pfizer Inc.’s pharmaceutical product, Toviaz ® , prior to the expiration of United States Patent Nos. 6,858,650(“the ‘650 patent”), 7,384,980 (“the ‘980 patent”), 7,855,230 (“the ‘230 patent”), 7,985,772 (“the‘772 patent”), and 8,338,478 (“the ‘478 patent”), which cover, interalia, Toviaz ® and/or its use.
On information, Lupin has submitted ANDA No. 204983 (“Lupin’s ANDA”) to the FDA, pursuant to 21 U.S.C. § 355(j), seeking approval to market fesoterodine fumarate extended-release tablets in 4 and 8 mg dosage strengths (“Lupin’sProduct”).
Case details:
Civil Action No. 1:13-cv-01153-UNA; no judge yet assigned.
Filed on June 28, 2013 in the U.S. District Court for the District of Delaware;
Complaint over Zydus:
On information belief, Zydus has submitted ANDA No. 204946 (“Zydus’s ANDA”) to the FDA, pursuant to 21 U.S.C. § 355(j), seeking approval to market fesoterodine fumarate extended-release tablets in 4 and 8 mg dosage strengths (“Zydus’sProduct”).
Case details:
Civil Action No. 1:13-cv-01154-UNA; no judge yet assigned.
Filed on June 28, 2013 in the U.S. District Court for the District of Delaware;
Complaint over Accordt:
Accord has submitted ANDA No. 205012(“Accord’s ANDA”) to the FDA, pursuant to 21 U.S.C. § 355(j), seeking approval to marketfesoterodine fumarate extended-release tablets in 4 and 8 mg dosage strengths (“Accord’sProduct”).
Case details:
Civil Action No. 1:13-cv-01155-UNA; no judge yet assigned.
Filed on June 28, 2013 in the U.S. District Court for the District of Delaware;